APOGEE THERAPEUTICS INC (APGE) Stock Price & Overview
NASDAQ:APGE • US03770N1019
Current stock price
The current stock price of APGE is 67.845 USD. Today APGE is up by 1.61%. In the past month the price decreased by -4.98%. In the past year, price increased by 67.6%.
APGE Key Statistics
- Market Cap
- 4.635B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.22
- Dividend Yield
- N/A
APGE Stock Performance
APGE Stock Chart
APGE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to APGE. When comparing the yearly performance of all stocks, APGE is one of the better performing stocks in the market, outperforming 85.84% of all stocks.
APGE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APGE. While APGE has a great health rating, there are worries on its profitability.
APGE Earnings
APGE Forecast & Estimates
22 analysts have analysed APGE and the average price target is 106.37 USD. This implies a price increase of 56.79% is expected in the next year compared to the current price of 67.845.
APGE Groups
Sector & Classification
APGE Financial Highlights
Over the last trailing twelve months APGE reported a non-GAAP Earnings per Share(EPS) of -4.22. The EPS decreased by -28.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.3% | ||
| ROE | -28.3% | ||
| Debt/Equity | 0 |
APGE Ownership
APGE Latest News, Press Relases and Analysis
APGE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.04 | 368.381B | ||
| AMGN | AMGEN INC | 15.35 | 189.472B | ||
| GILD | GILEAD SCIENCES INC | 15.96 | 175.4B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 114.717B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.74 | 78.668B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.92 | 41.749B | ||
| INSM | INSMED INC | N/A | 30.759B | ||
| NTRA | NATERA INC | N/A | 28.033B | ||
| BIIB | BIOGEN INC | 11.34 | 26.756B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.68 | 23.245B | ||
| MRNA | MODERNA INC | N/A | 20.695B | ||
| EXAS | EXACT SCIENCES CORP | 341.43 | 19.805B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.443B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About APGE
Company Profile
Apogee Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2023-07-14. The firm is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
Company Info
IPO: 2023-07-14
APOGEE THERAPEUTICS INC
221 Crescent St., Building 17, Suite 102B
Waltham MASSACHUSETTS US
Employees: 196
Phone: 13026587581
APOGEE THERAPEUTICS INC / APGE FAQ
What does APOGEE THERAPEUTICS INC do?
Apogee Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2023-07-14. The firm is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
Can you provide the latest stock price for APOGEE THERAPEUTICS INC?
The current stock price of APGE is 67.845 USD. The price increased by 1.61% in the last trading session.
What is the dividend status of APOGEE THERAPEUTICS INC?
APGE does not pay a dividend.
How is the ChartMill rating for APOGEE THERAPEUTICS INC?
APGE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for APOGEE THERAPEUTICS INC?
APOGEE THERAPEUTICS INC (APGE) operates in the Health Care sector and the Biotechnology industry.
Is APOGEE THERAPEUTICS INC (APGE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on APGE.
What is the outstanding short interest for APOGEE THERAPEUTICS INC?
The outstanding short interest for APOGEE THERAPEUTICS INC (APGE) is 17.53% of its float.